Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is titled “분기보고서 (제74기 1분기)” covering the period January 1 to March 31, 2026, and contains the full interim financial statements, business overview, MD&A, auditor’s opinion, and detailed financial tables. This is clearly a comprehensive quarterly report, matching the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-06 Korean
최대주주등소유주식변동신고서
Regulatory Filings
2026-05-06 Korean
최대주주등소유주식변동신고서
Regulatory Filings
2026-04-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 99% confidence The document is titled “주식등의 대량보유상황보고서” (“Report on Large Shareholdings”), filed under Korea’s Capital Markets Act (공시법규 제147조). It provides detailed disclosure of a major shareholder’s and related parties’ holdings, changes, and contract terms, matching the definition of “Major Shareholding Notification” (threshold-crossing disclosures). This is not an earnings release, AGM material, or proxy solicitation but a statutory major shareholding report to regulators.
2026-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a mandatory ownership report by an executive and major shareholder (‘임원ㆍ주요주주 특정증권등 소유상황보고서’) detailing insider shareholdings and transactions (e.g., purchase on‐market, holdings before and after). This matches the definition of Director's Dealing filings reporting personal share transactions by company directors and executives.
2026-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.